The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model
- PMID: 20022105
- DOI: 10.1016/j.biomaterials.2009.11.106
The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model
Abstract
To circumvent carrier related obstacles, we developed a biodegradable, folate conjugated poly (ester amine) (FP-PEA) that mediates high level folate receptor (FR) mediated endocytosis in vitro as well as in vivo. We report the efficacy of a therapeutic strategy that combines the potency of FP-PEA based on polycaprolactone (PCL) and low molecular weight polyethylenimine (LMW-PEI) with the tumor targeting potential of receptor mediated endocytosis. When tested on cells in culture, FP-PEA was found to retain high affinity for FR-positive cells compared with PEA without folate moiety (P-PEA). The FR specific activity of FP-PEA was drastically decreased in the presence of an excess free folic acid and very less significant transfection was detected against FR-negative cells. FP-PEA showed marked anti-tumor activity against FR-positive human KB tumors in nude mice with no evidence of toxicity during and after therapy using TAM67 gene. Furthermore, the therapeutic effect occurred in the apparent absence of weight loss or noticeable tumor apoptosis. In contrast, no significant anti-tumor activity was observed in P-PEA treated mice which were co dosed with an excess of FR, thus demonstrating the target specific gene delivery. Furthermore, anti-tumor activity with PEA without folic acid moiety (P-PEA) proved not to be effective against xenograft mice model with KB cells when administered at the same dose to that of FP-PEA. Taken together, these results indicate that FP-PEA is highly effective gene carrier capable of producing therapeutic benefit in xenograft mice model without any sign of toxicity.
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
Similar articles
-
Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.Cancer Res. 2007 Jul 1;67(13):6376-82. doi: 10.1158/0008-5472.CAN-06-3894. Cancer Res. 2007. PMID: 17616697
-
Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.Cancer Res. 2008 Dec 1;68(23):9839-44. doi: 10.1158/0008-5472.CAN-08-2341. Cancer Res. 2008. PMID: 19047164
-
Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.Cancer Chemother Pharmacol. 2010 May;66(1):43-52. doi: 10.1007/s00280-009-1132-4. Epub 2009 Sep 25. Cancer Chemother Pharmacol. 2010. PMID: 19779718
-
Folate-mediated targeting of therapeutic and imaging agents to cancers.Crit Rev Ther Drug Carrier Syst. 1998;15(6):587-627. Crit Rev Ther Drug Carrier Syst. 1998. PMID: 9883391 Review.
-
[Folate receptor-mediated antitumor drugs].Yao Xue Xue Bao. 2009 Feb;44(2):109-14. Yao Xue Xue Bao. 2009. PMID: 19408677 Review. Chinese.
Cited by
-
Development of novel, biocompatible, polyester amines for microglia-targeting gene delivery.RSC Adv. 2021 Nov 16;11(58):36792-36800. doi: 10.1039/d1ra06277h. eCollection 2021 Nov 10. RSC Adv. 2021. PMID: 35494387 Free PMC article.
-
Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles.PLoS One. 2014 May 14;9(5):e97358. doi: 10.1371/journal.pone.0097358. eCollection 2014. PLoS One. 2014. PMID: 24828815 Free PMC article.
-
Nanoparticle-induced neutrophil apoptosis increases survival in sepsis and alleviates neurological damage in stroke.Sci Adv. 2019 Nov 6;5(11):eaax7964. doi: 10.1126/sciadv.aax7964. eCollection 2019 Nov. Sci Adv. 2019. PMID: 31723603 Free PMC article.
-
Therapeutic efficiency of folated poly(ethylene glycol)-chitosan-graft-polyethylenimine-Pdcd4 complexes in H-ras12V mice with liver cancer.Int J Nanomedicine. 2013;8:1489-98. doi: 10.2147/IJN.S42949. Epub 2013 Apr 16. Int J Nanomedicine. 2013. PMID: 23620665 Free PMC article.
-
Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy.Int J Nanomedicine. 2014 Jul 29;9:3509-26. doi: 10.2147/IJN.S63717. eCollection 2014. Int J Nanomedicine. 2014. PMID: 25114522 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical